News

Five New European Bauhaus Lighthouse demonstrators projects selected

Published on | 3 years ago

Programmes Missions New European Bauhaus

The results of the mission call Support the deployment of lighthouse demonstrators for the New European Bauhaus initiative in the context of Horizon Europe missions (HORIZON-MISS-2021-NEB-01) are announced. Five projects have been selected for this call and will each receive a funding of  approximately €5 million to implement their plans in 13 EU Member States and Associated Countries: Belgium, Czechia, Germany, Denmark, Greece, Croatia, Italy, Latvia, Netherlands, Slovenia, Portugal, Norway and Turkey.

The selected projects will bring innovative ideas and solutions in helping to point the way forward for other New European Bauhaus actions and will also contribute to the EU Missions.

To read the full press release click here.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1728 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.